---
title: "Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295971223.md"
description: "Plus Therapeutics reported a widened Q2 FY26 net loss of $9.01 million, reversing from prior net income. Operating losses increased to $9.06 million due to expanded CNSide commercialization and REYOBIQ Phase 2 spending. Grant revenue dropped 70.43% to $411,000 as CPRIT support decreased. Cash reserves remained stable at $8.6 million. The company rebranded as Cerenome in August and continues REYOBIQ trial enrollment, with ReSPECT-GBM data expected in Q1 2027."
datetime: "2026-08-14T20:16:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295971223.md)
  - [en](https://longbridge.com/en/news/295971223.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295971223.md)
generator: "portal-rs"
---

# Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million

-   Plus Therapeutics posted a Q2 net loss of USD 9 million, or USD 1.31 a share, swinging from net income of USD 5.2 million. \* Operating loss widened to USD 9.1 million from USD 1.5 million, on expanded CNSide commercialization and REYOBIQ Phase 2 spending. \* Grant revenue fell 70.43% to USD 411,000, reflecting lower CPRIT support for REYOBIQ in leptomeningeal metastases. \* Cash, cash equivalents and investments totaled USD 8.6 million at June 30, unchanged from Dec. 31. \* Rebranded as Cerenome effective Aug. 3; continued REYOBIQ trial enrollment, with ReSPECT-GBM data expected in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141615PRIMZONEFULLFEED9810550) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)

## Related News & Research

- [Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook](https://longbridge.com/en/news/296058426.md)
- [Plus Therapeutics flags availability of CNS cancers guidelines update release](https://longbridge.com/en/news/292616746.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Norcod to webcast Q2 and first-half 2026 results presentation](https://longbridge.com/en/news/296225973.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**